ROCKVILLE, Md. — RegeneRx Biopharmaceuticals Inc. (OTC Bulletin Board: RGRX) reported Wednesday that in a Michigan trial, researchers found that Thymosin Beta 4 (Tβ4) promotes statistically significant recovery of peripheral neuropathy in type II diabetic mice.
Included is recovery of neurovascular dysfunction in the sciatic nerve and recovery of neurological function.
Peripheral neuropathy is one of the most common complications of diabetes mellitus and affects 60 to 70 percent of patients with diabetes.
According to the research team, “These data indicate that Tβ4 likely acts on endothelial cells and Schwann cells to preserve and/or restore vascular function in the sciatic nerve which facilitates improvement of peripheral nerve function under diabetic neuropathy. Thus, Tβ4 has potential for the treatment of diabetic peripheral neuropathy.”
The study was conducted by researchers at The Henry Ford Hospital in Detroit and Oakland University in Rochester, and published by Wang, L., et al., “Thymosin 4 promotes the recovery of peripheral neuropathy in type II diabetic mice,” Neurobiol. Dis. (2012), http://dx.doi.org/10.1016/j.nbd.2012.08.002.
RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, two strategic licensing agreements in China and the EU, and has an extensive worldwide patent portfolio covering its products.
More at www.regenerx.com.